Basic Information
Symvivo is a clinical-stage gene therapy company developing oral DNA vaccines for life-threatening diseases such as COVID-19, with broader therapeutic potential in intravenous treatments for cancer and genetic disorders. Our current projects span clinical and preclinical spaces in oncology, ischemic heart disease, vaccines, and rare diseases.
Symvivo Corporation
BritishColumbia,Canada
unclear
January 01, 2013
general@symvivo.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios